PrimeRFP SCOUT · Federal Contract Recompete Brief · GSA MAS

75F40119F80339CDER PHASE II biosimilars ORDER — Palladian Partners, Inc

Palladian Partners, Inc holds $30.9M across 46 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 29, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Fda Office Of Acq Grant Svcs

Awarding office

Palladian Partners, Inc

Recipient

Sep 29, 2022

PoP end

$-132,239.11

Obligated

$1M

Potential

541820

NAICS

R408

PSC

GSA MAS

Vehicle

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Palladian Partners, Inc — $90

Contract facts

Federal

Contract number75F40119F80339

Also listed asGS23F0270L-75F40119F80339

AgencyFda Office Of Acq Grant Svcs

Awarding officeFda Office Of Acq Grant Svcs

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentPalladian Partners, Inc

CAGE1HDV7

UEISJGQXJEFBKC5

NAICS541820

No full NAICS 541820 intel page yet. Browse NAICS intelligence

PSCR408

VehicleGSA MAS

Parent IDIQ / IDVGS23F0270L

Place of performanceSILVER SPRING MD

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startAug 26, 2019

PoP end (current)Sep 29, 2022

Obligated$-132,239.11

Current value$1M

Potential value$1M

CDER PHASE II BIOSIMILARS ORDER is a federal award for Fda Office Of Acq Grant Svcs held by Palladian Partners, Inc. Estimated value $1M ($-132,239.11 obligated). Current period of performance ends Sep 29, 2022. Last award drew 1 bidder. Place of performance: SILVER SPRING MD.

Recompete timing

Public

● Past PoP end (1422 days ago)

Current PoP ended Sep 29, 2022 (1422 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Palladian Partners, Inc — $30.9M obligated across 46 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($30.9M) · all agencies

Department of Health and Human Services (HHS)$30.9M · 100%Department of Agriculture (USDA)$33K · 0%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75F40119F80339?

75F40119F80339 (CDER PHASE II biosimilars ORDER) is a Fda Office Of Acq Grant Svcs award with a potential value of $1M, currently held by Palladian Partners, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75F40119F80339?

Fda Office Of Acq Grant Svcs awarded 75F40119F80339 to Palladian Partners, Inc (potential $1M).

Who is the incumbent on 75F40119F80339?

Palladian Partners, Inc is the incumbent with $30.9M across 46 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2022.

When does Palladian Partners, Inc’s 75F40119F80339 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 23, 2026 · refreshed monthlyLatest procurement action Feb 28, 2023